Please login to the form below

Not currently logged in
Email:
Password:

chronic cough

This page shows the latest chronic cough news and features for those working in and with pharma, biotech and healthcare.

Menlo slumps as itching drug fails mid-stage trial

Menlo slumps as itching drug fails mid-stage trial

Menlo Therapeutics has said its phase 2 trial of serlopitant in chronic itching (pruritus) is a bust, blaming the result on a high placebo response rate. ... like rival Vanda Therapeutics did with its rival NK1 drug tradipitant this week – as well as

Latest news

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    AF-219, a selective, non-narcotic, oral P2X3 antagonist, is currently in a phase 2b trial for the treatment of refractory, chronic cough and in a phase 2 trial in idiopathic ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...